Oct 22nd 2013 - Edison Investment Research today published a report on Futura Medical (FUM.L, LSE:FUM, LON:FUM) entitled "CSD500 Gets Its CE Mark". In summary, the report says:
The award of a CE mark for Futura Medical’s performance-enhancing condom CSD500 means that it can be marketed in all European countries, as well as a number of other markets that recognise the CE mark. Church & Dwight, the US consumer group that owns the Trojan brand, can now formalise its launch plans for CSD500 in its licensed European territories. Our valuation remains £66m, or 85p per share.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »